ROS1 and cancer: Various studies have reported cases of multi-target sequential intervention in the treatment of various cancer types: for patients with triple-negative breast cancer expressing MYCN, the combination of BET inhibitors and MEK inhibitors can synergistically inhibit tumor growth (Schafer et al., 2020); in patients with melanoma, combined inhibition of PD-1, BRAF and MEK can significantly prolong patient survival (Dummer et al., 2020); for advanced lung cancer, combined intervention of TRA, ROS1 and ALK targets reduces brain metastasis in patients (Drilon et al., 2017).